Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Horn on Incorporating T790M-Mutant NSCLC Agents Into NCCN Guidelines

April 2nd 2016

Leora Horn, MD, MSc, clinical director, Thoracic Oncology Program, assistant vice chancellor for faculty development, Vanderbilt-Ingram Cancer Center, provides her thoughts on how agents targeted T790M-mutant NSCLC will be incorporated into NCCN guidelines.

Erlotinib Bests Gefitinib in Phase III NSCLC Study

March 29th 2016

Treatment with gefitinib failed to show noninferiority compared with erlotinib for patients with pretreated nonâ€“small cell lung cancer.

Dr. Heather Wakelee on What to Do When Resistance to EGFR TKIs Emerges

March 24th 2016

Heather Wakelee, MD associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses treating EGFR-mutant patients with lung cancer who are resistant to EGFR tyrosine kinase inhibitors (TKIs).

Combining and Sequencing Immunotherapies in NSCLC

March 18th 2016

Emerging Checkpoint Inhibitors for Lung Cancer

March 18th 2016

Immune-Related Response Criteria in NSCLC

March 18th 2016

Checkpoint Inhibitors in NSCLC

March 18th 2016

Less Common Mutations in Lung Adenocarcinoma

March 18th 2016

ALK-Positive Lung Cancer

March 18th 2016

Emerging Agents for Advanced EGFR+ Lung Cancer

March 18th 2016

Treatment of Relapsed EGFR-Mutant Adenocarcinoma

March 18th 2016

Upfront EGFR-Targeted Therapy

March 18th 2016

Second-Line Therapies for Non-Driver NSCLC

March 18th 2016

Chemotherapy for Advanced Lung Cancer

March 18th 2016

The Future of Biomarker Testing in Lung Cancer

March 18th 2016

PD-L1 Testing in Advanced Lung Cancer

March 18th 2016

Practical Advice on Molecular Testing in Lung Cancer

March 18th 2016

Importance of Molecular Testing in Lung Cancer

March 18th 2016

Expert on PD-L1/CTLA-4 Blockade and Future of Immunotherapy in Lung Cancer

March 17th 2016

Scott J. Antonia, MD, discusses how the combination of the PD-L1 inhibitor durvalumab and the CTLA-4 inhibitor tremelimumab, showed antitumor activity in patients with locally advanced or metastatic nonâ€“small cell lung cancer, irrespective of PD-L1 status.

Dr. Chandra Belani on Atezolizumab in NSCLC

March 16th 2016

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses atezolizumab in non-small cell lung cancer (NSCLC).